ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1169

Efficacy of Intravenous Immunoglobulin (Octagam 10%) on Pulmonary Manifestations in Patients with Dermatomyositis: Results from the ProDERM Study

Rohit Aggarwal1, christina Charles-Schoeman2 and Joachim Schessl3, and the ProDERM Investigators, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 2UCLA Medical Center, Santa Monica, CA, 3Friedrch-Baur-Institut; Ludwig-Maximilians University of Munich, Munich, Germany

Meeting: ACR Convergence 2024

Keywords: clinical trial, dermatomyositis, Myopathies, pulmonary

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) and other pulmonary manifestations are a major cause of mortality and morbidity in patients with dermatomyositis (DM). The ProDERM study was a randomized Phase 3 study designed to evaluate the efficacy and safety of intravenous immunoglobulin (IVIg) in adult DM patients. Here, we performed a post-hoc analysis of ProDERM to assess the effect of IVIg on pulmonary symptoms of DM.

Methods: ProDERM was a placebo-controlled, double-blind, multicenter Phase 3 study involving two phases. From Weeks 0 to 16, patients were randomized to receive 2.0 g/kg IVIg or placebo (saline) every 4 weeks. This was followed by an open-label extension period from Weeks 16 to 40, during which all eligible patients received IVIg for six additional cycles. Pulmonary symptoms of DM were assessed by the physician and reported using the Myositis Disease Activity Assessment Tool (MDAAT). Visual analog scales (VAS) were scored over 10 cm to quantify overall pulmonary disease activity, with higher score indicating worse disease. Physicians also reported presence/absence of pulmonary symptoms of dysphonia, dyspnea or cough from active reversible ILD, and dyspnea from respiratory muscle weakness on MDAAT.

Results: Of 95 patients with DM in the ProDERM study, 98% met the probable or definite criteria for inflammatory myopathy according to the 2017 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria for idiopathic inflammatory myopathies. Of all patients, 59 (62.1%) had baseline pulmonary VAS ≤0.5 cm (Figure 1), indicating no myositis lung involvement. By Week 40, this increased to 68 of the 88 patients with available data (77.3%; p=0.007).

As patients with baseline pulmonary VAS ≤0.5 cm were unlikely to improve in terms of pulmonary manifestations during the trial, improvement in pulmonary score was examined only in the 36 patients with baseline VAS >0.5 cm (Figure 2). For patients with data at both baseline and Week 16, those on IVIg (n=12) experienced a mean decrease of 1.15 cm (37.7%; p=0.001) vs. 0.17 cm (6.5%) in patients on placebo (n=21; p=0.50). From baseline to Week 40, with patients on placebo having switched to IVIg, the mean decrease for the combined cohort (n=32 patients with data) was 1.08 cm (38.2%; p< 0.001).

Among all patients, the percentage with dyspnea from respiratory muscle weakness, or from ILD, both decreased from baseline numerically at Weeks 16 and 40, but neither reached statistical significance (Table 1). The percentage of patients with dysphonia decreased from 20% at baseline to 8% at Week 40 (p=0.04).

Conclusion: IVIg may have favorable treatment effects on active pulmonary manifestations of DM. Further studies are warranted.

Supporting image 1

Figure 1 MDAAT pulmonary VAS score at baseline and Week 40

Supporting image 2

Figure 2 Change in MDAAT pulmonary VAS score from baseline*

Supporting image 3

Table 1 N° of patients with specific pulmonary symptoms at Week 16 and Week 40


Disclosures: R. Aggarwal: Alexion, 2, ANI Pharmaceuticals, 2, Argenx, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, CabalettaBio, 2, Capella Bioscience, 2, Capstanx, 2, Corbus, 2, CSL Behring, 2, EMD Serono, 2, 5, Galapagos, 2, Horizon Therapeutics, 2, I-Cell, 2, Immunovant, 2, Janssen, 1, 2, 5, Kezar, 2, Kyverna, 2, Lilly, 2, Mallinckrodt, 5, Manta Medicines Corporation, 2, Merck, 2, Novartis, 2, Nuvig Therapeutics, 2, Octapharma, 2, Pfizer, 2, 5, Q32, 5, Roivant, 2, Sanofi, 2, Teva, 2; c. Charles-Schoeman: AbbVie/Abbott, 2, 5, Alexion, 5, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, 5, CSL Behring, 5, Galapagos, 2, Janssen, 5, Octapharma, 2, 5, Pfizer, 2, 5, Priovant, 5, Recludix, 2; J. Schessl: Octapharma, 1, 2.

To cite this abstract in AMA style:

Aggarwal R, Charles-Schoeman c, Schessl J. Efficacy of Intravenous Immunoglobulin (Octagam 10%) on Pulmonary Manifestations in Patients with Dermatomyositis: Results from the ProDERM Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/efficacy-of-intravenous-immunoglobulin-octagam-10-on-pulmonary-manifestations-in-patients-with-dermatomyositis-results-from-the-proderm-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-intravenous-immunoglobulin-octagam-10-on-pulmonary-manifestations-in-patients-with-dermatomyositis-results-from-the-proderm-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology